A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation
Hodgkin lymphoma variant of Richter’s transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinb...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2024-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2024/7612622 |
| _version_ | 1797282431438422016 |
|---|---|
| author | Benjamin Heyman Michael Choi Thomas J. Kipps |
| author_facet | Benjamin Heyman Michael Choi Thomas J. Kipps |
| author_sort | Benjamin Heyman |
| collection | DOAJ |
| description | Hodgkin lymphoma variant of Richter’s transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed. |
| first_indexed | 2024-03-07T17:13:55Z |
| format | Article |
| id | doaj.art-76689a3d37e54650ba260a4c78567ae6 |
| institution | Directory Open Access Journal |
| issn | 2090-6579 |
| language | English |
| last_indexed | 2024-03-07T17:13:55Z |
| publishDate | 2024-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj.art-76689a3d37e54650ba260a4c78567ae62024-03-03T00:00:02ZengHindawi LimitedCase Reports in Hematology2090-65792024-01-01202410.1155/2024/7612622A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s TransformationBenjamin Heyman0Michael Choi1Thomas J. Kipps2Division of Regenerative MedicineDivision of Hematology/OncologyCenter for Novel TherapeuticsHodgkin lymphoma variant of Richter’s transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.http://dx.doi.org/10.1155/2024/7612622 |
| spellingShingle | Benjamin Heyman Michael Choi Thomas J. Kipps A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation Case Reports in Hematology |
| title | A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation |
| title_full | A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation |
| title_fullStr | A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation |
| title_full_unstemmed | A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation |
| title_short | A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation |
| title_sort | a avd for treatment of hodgkin lymphoma variant of richter s transformation |
| url | http://dx.doi.org/10.1155/2024/7612622 |
| work_keys_str_mv | AT benjaminheyman aavdfortreatmentofhodgkinlymphomavariantofrichterstransformation AT michaelchoi aavdfortreatmentofhodgkinlymphomavariantofrichterstransformation AT thomasjkipps aavdfortreatmentofhodgkinlymphomavariantofrichterstransformation |